(MENAFN- GlobeNewsWire - Nasdaq) SNS Insider projects the U.S. Human Microbiome Market to grow from USD 0.51 Billion in 2025E to USD 1.94 Billion by 2033, at a CAGR of 18.27%.

Austin, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Human Microbiome Market Size & Growth Analysis

According to SNS Insider, the global Human Microbiome Market was valued at USD 1.39 billion in 2025E and is projected to reach USD 5.45 billion by 2033, growing at a CAGR of 18.62% during 2026–2033. The U.S. led the market with USD 0.51 billion in 2025E and is expected to reach USD 1.94 billion by 2033, supported by robust clinical trials, breakthroughs in microbiome-based therapeutics and diagnostics, and strong commercial interest in personalized gut health solutions.

Expanding clinical research programs, strategic collaborations between biotech companies and research institutions, along with increased public awareness of the gut-brain and gut-immune axis, are propelling the market forward. Innovations in next-generation sequencing, metabolomics, and bioinformatics are transforming the way microbiome solutions are developed, regulated, and commercialized globally.

Get free Sample Report of Human Microbiome Market:

Human Microbiome Market Overview

The human microbiome plays a critical role in immunity, metabolism, and overall well-being. With the rising prevalence of gastrointestinal and autoimmune disorders, interest in leveraging the microbiome for therapeutic and preventive healthcare is accelerating. The industry is shifting from niche academic research to mainstream clinical and commercial applications, particularly in precision medicine, personalized nutrition, and next-generation therapeutics.

The U.S. remains a leading market, benefiting from a strong regulatory ecosystem, high R&D spending, and rapid adoption of innovative therapies. Global investments are also increasing in Asia-Pacific and Europe, as governments and private companies alike see microbiome science as a cornerstone of the future of healthcare.

Major Players Analysis Listed in the Human Microbiome Market Report are

• Seres Therapeutics
• Ferring Pharmaceuticals
• Nestlé Health Science
• Seed Health
• Finch Therapeutics
• Vedanta Biosciences
• 4D pharma
• Synlogic
• Assembly Biosciences
• Eligo Bioscience
• Locus Biosciences
• Microba Life Sciences
• Viome Life Sciences
• MaaT Pharma
• BioGaia
• ExeGi Pharma
• Infant Bacterial Therapeutics
• Biohm Health
• Pendulum Therapeutics
• Second Genome

Human Microbiome Market Report Scope

Report Attributes	Details
Market Size in 2025	USD 1.39 Billion
Market Size by 2033	USD 5.45 Billion
CAGR	CAGR of 18.62% From 2026 to 2033
Base Year	2025
Forecast Period	2026-2033
Historical Data	2022-2024
Key Segments	By Product (Probiotics, Prebiotics, Diagnostic Devices, Drugs, Others) By Application (Therapeutics, Diagnostics, Personalized Nutrition & Wellness, Research & Development, Others) By Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, Infectious Diseases, Gastrointestinal Disorders, Others) By Technology (Genomics, Metabolomics, Proteomics, Transcriptomics, Others) By End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
Regional Analysis/Coverage	North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).

Segmentation Analysis:

By Distribution Channel

Hospital pharmacies dominate the market with a 54.98% share in 2025, driven by their strong infrastructure, trusted distribution networks, and ability to provide personalized consultation and immediate access to prescribed therapeutics. Meanwhile, online pharmacies are projected to register the fastest CAGR of 20.35%, fueled by the growing adoption of e-commerce platforms, expanding digital health ecosystems, and convenience in home delivery.

By Product

Drugs account for the largest market share of 39.12% in 2025 due to their clinical efficacy, regulatory approvals, and extensive R&D investments by major pharmaceutical players. Conversely, probiotics are expected to grow at the fastest CAGR of 20.34%, driven by a growing awareness of gut health, preventive healthcare trends, and consumer preference for natural, microbiome-friendly supplements.

By Application

Therapeutics lead the market with 81.85% share in 2025, as microbiome-based therapies and drugs gain traction in treating chronic and infectious diseases. Meanwhile, the diagnostics segment is projected to grow at the fastest CAGR of 19.95%, propelled by advancements in sequencing technologies, demand for precision medicine, and growing awareness of microbiome profiling for disease risk assessment.

By Disease

Gastrointestinal disorders dominate with a 34.75% market share in 2025 due to the microbiome's critical role in gut health and digestion. On the other hand, autoimmune disorders are expected to record the fastest CAGR of 20.05%, as emerging studies link gut dysbiosis to immune system regulation.

By Technology

Genomics holds the highest share of 44.98% in 2025, driven by the growing use of next-generation sequencing (NGS), metagenomic analysis, and bioinformatics tools to decode complex microbial ecosystems. Metabolomics, forecasted to grow at the fastest CAGR of 20.12%, is gaining momentum due to its ability to profile metabolic interactions between microbes and hosts.

By End-User

Hospitals & clinics dominate with a 49.92% share in 2025, supported by their role as primary centers for diagnosis, treatment, and clinical research in microbiome-based healthcare. In contrast, pharmaceutical and biotechnology companies are projected to grow at the fastest CAGR of 20.20%, driven by intensive R&D investment, strategic collaborations, and expanding pipelines of microbiome-based therapeutics and diagnostic solutions.

Buy the Human Microbiome Market Report Now:

By Region

North America accounted for 44.78% of the global Human Microbiome Market in 2025, with over 1,350 active microbiome-based clinical trials conducted across the region. The market is mostly driven by therapeutic and diagnostic uses, although it is rapidly being joined by probiotics and personalized nutrition.

The Asia-Pacific Human Microbiome Market is projected to grow at a CAGR of 19.89% during 2026–2033. The market is driven by the increases in gut health awareness and biotechnological investment, along with personalized nutrition initiatives, and the development of research forsulin-based products in the region.

Recent News:

• In May 2025 , Seres presented expanded biomarker data from its SER-155 Phase 1b study, supporting microbiome-based therapeutics for gut health
• In April 2025 , Ferring expanded manufacturing capacity for Rebyota and ADSTILADRIN®, addressing rising demand for microbiome therapies.
• Rebiotix (Ferring) launched a hospital distribution program to enhance global access to microbiome-based therapeutics.
• 4D Pharma advanced its live biotherapeutic pipeline, focusing on metabolic and inflammatory conditions.
• Enterome expanded its biomarker discovery program using advanced genomic and metabolomic platforms.

Exclusive Sections of the Report (The USPs):

• MARKET ADOPTION & USAGE INSIGHTS – helps you assess the growth trajectory of microbiome therapeutics through metrics such as the annual increase in microbiome-based clinical trials, rising patient adoption rates, and the expanding volume of microbiome diagnostic tests across major regions.
• PRODUCT & PIPELINE DEVELOPMENT TRACKER – provides visibility into the pace of product innovation, highlighting the yearly launches of probiotics, prebiotics, and microbiome-targeted drugs, along with the percentage of active products under development and personalized nutrition programs entering the market.
• RESEARCH & INNOVATION METRICS – evaluates the scientific momentum of the market through the number of patents filed, peer-reviewed publications released annually, and growing academia–industry collaborations driving translational microbiome research.
• TECHNOLOGY ADOPTION INDEX – analyzes the penetration of advanced technologies such as genomics, metabolomics, proteomics, and transcriptomics in microbiome research, helping you understand which technological domains are gaining dominance and research funding priority.
• DIAGNOSTIC ADOPTION RATE – captures the rate at which hospitals, laboratories, and research centers are integrating microbiome-based diagnostic platforms, reflecting the shift from experimental use to clinical implementation.
• INNOVATION PIPELINE INTELLIGENCE – helps investors and stakeholders identify high-growth opportunities by tracking innovation intensity, ongoing clinical trials, and R&D collaborations shaping the next generation of microbiome-based therapies and diagnostics.

Access Complete Report Details of Human Microbiome Market Analysis & Outlook:

[For more information or need any customization research mail us at ...]

About Us:

S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: ...

MENAFN14102025004107003653ID1110194768